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Abstract: Mucosal melanomas (MM) are rare aggressive cancers in humans, and one of the most
common forms of oral cancers in dogs. Similar biological and histological features are shared
between MM in both species, making dogs a powerful model for comparative oncology studies of
melanomas. Although exome sequencing recently identified recurrent coding mutations in canine
MM, little is known about changes in non-coding gene expression, and more particularly, in canine
long non-coding RNAs (lncRNAs), which are commonly dysregulated in human cancers. Here, we
sampled a large cohort (n = 52) of canine normal/tumor oral MM from three predisposed breeds
(poodles, Labrador retrievers, and golden retrievers), and used deep transcriptome sequencing to
identify more than 400 differentially expressed (DE) lncRNAs. We further prioritized candidate
lncRNAs by comparative genomic analysis to pinpoint 26 dog–human conserved DE lncRNAs,
including SOX21-AS, ZEB2-AS, and CASC15 lncRNAs. Using unsupervised co-expression network
analysis with coding genes, we inferred the potential functions of the DE lncRNAs, suggesting
associations with cancer-related genes, cell cycle, and carbohydrate metabolism Gene Ontology (GO)
terms. Finally, we exploited our multi-breed design to identify DE lncRNAs within breeds. This
study provides a unique transcriptomic resource for studying oral melanoma in dogs, and highlights
lncRNAs that may potentially be diagnostic or therapeutic targets for human and veterinary medicine.
Keywords: mucosal melanoma; dogs; transcriptome sequencing; long non-coding RNAs (lncRNAs)
1. Introduction
Mucosal melanomas (MM) are the most frequent form of melanomas in dogs, and they display
more aggressive behavior in comparison to cutaneous melanomas. Dogs are spontaneously affected,
with specific breeds developing MM with clinical features that are similar to human melanomas [1]. Dog
breeds with high melanoma risk have been proposed as relevant natural models for the comparative
oncology of melanomas, especially for deciphering their non-UV-dependent pathways, and for
developing clinical trials that are based on homologous melanoma subtypes [1,2].
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Recently, genomic studies have been conducted, to identify driver genomic alterations that are
involved in canine MM [3,4], using exome sequencing to focus on the genetic landscape of somatic
mutations in protein-coding genes (messenger RNAs; mRNAs). A consequence of cumulative genetic
and epigenetic alterations in coding and non-coding genes is reflected by the study of gene expression,
which has not yet been investigated in detail in canine model cancers. Despite the recent identification
of thousands of canine long non-coding RNAs (lncRNA) [5,6], little is known about their impact in dog
cancers, although they constitute an extensive component of dog genomes [7–9]. In humans, lncRNA
expression is recurrently altered in many types of cancers [10–12], including melanomas [13]. From
the first annotation of the melanoma-associated lncRNA SPRY4-IT1 [14] to the recent identification
of recurrent amplifications of SAMMSON, a dozen of lncRNAs have been functionally validated
in cutaneous melanomas [15]. Because lncRNAs are expressed in a tissue-specific manner in both
humans [8,16] and dogs [6], they represent a vast and still unexplored repertoire of potential targets
and/or biomarkers for comparative oncology approaches.
Here, we analyzed a large cohort of canine MM transcriptomes from three breeds, sampled from
the oral cavity (n = 52). We quantified differential gene expression by controlling for cell heterogeneity,
using a signature-based method, and we assessed transcriptional networks by using co-expression
analysis. We showed that lncRNA expression profiles discriminate between normal and tumor samples,
and identified a significant amount of deregulation for 400 lncRNAs. Gene-set enrichment analyses
were performed using co-expression networks of lncRNA:mRNA, to acquire associated GO enrichments
for all-breed and breed-specific DE lncRNAs. Furthermore, we conducted dog-human orthologous
relationship analyses to identify conserved lncRNAs, with potential interest in human melanomas.
Altogether, this study provides an in-depth characterization of lncRNAs that are dysregulated in canine
oral melanomas, and prioritizes potential biomarker lncRNAs by investigating their conservation and
co-expression networks. Our findings provide a novel transcriptomic resource with detailed sample
characterization for the comparative oncology of melanomas in dogs and humans.
2. Materials and Methods
2.1. Canine RNA Samples: Extraction and Sequencing
In total, 39 dogs from three breeds (GRET: golden retrievers, LABR: Labrador retrievers, and
PODL: poodles) were sampled with either tumor-only (n = 26) or matched tumor/normal samples (n =
13 × 2) (totaling 52 samples) from the two biobanks, “Cani-DNA_BRC”, which is part of the CRB-Anim
infrastructure, and the Canine Comparative Oncology and Genomics Consortium (CCOGC). Samples
were collected in the course of the health management of the dogs, by DVM veterinarians, with the
owner’s consent, and the diagnosis was performed through histopathological analyses (CNRS ethical
board, France (35-238-13)). Material was collected at surgery, then stored in RNAlater, and the diagnosis
of mucosal melanoma was evaluated by specialized veterinarians after histological examinations of
the samples.
For all of the 52 samples, RNAs were extracted by using RNA II NucleoSpin Kits according
to the manufacturer’s instructions (Macherey-Nagel, Hoerdt, France) then polyadenylated RNAs
(polyA+) were selected and sequenced at the BROAD sequencing platform, in a paired-end and
stranded fashion, using HiSeq-2000 Illumina technology (BROAD Genomics Platform, Cambridge,
MA, USA), at a mean depth of 107.4 million reads per sample. The RNA-Seq data is available in
European Nucleotide Archive.
We used the “canFam3.1-plus” annotation [5,6] containing 10,444 lncRNAs and 21,810
protein-coding genes as the reference annotation, and the canFam3.1 assembly version as the genome
reference [16]. Based on the protocol described in Djebali et al. [17], FASTQ reads were aligned, both on
the transcriptome and on the genome, using the STAR program (v2.5.0a) [18]. Finally, gene and isoform
expression levels were estimated in both normalized (TPM: transcripts per million) and un-normalized
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(raw count as required by DE tools) with the RSEM program (v1.2.25) [19] for each sample individually,
and then merged in order to obtain a matrix expression file, with genes in rows and samples in columns.
2.2. Analysis by DESeq2 using a Multi-Factor Design including Cell-Type Heterogeneity
The matrix of reads counts, including lncRNAs and mRNA genes, was used by DESeq2 (v1.22.2) [20]
to compute differentially expressed genes. Given the cellular heterogeneity between healthy and
tumor samples, we used the xCell program (v1.12) [21] to compute cell-type enrichment from our
gene expression data, based on the reference signature set of 64 immune and stroma human cell types
(Supplementary Materials Figure S1). The cell-type enrichment scores for keratinocytes, melanocytes,
and skeletal muscle cells were then included in the DESeq2 design, in order to specifically control
for DE genes involved in the tumor condition, and not in the differentiation between cell types
(e.g., keratinocytes versus melanocytes). To control for other covariates, we included breed and sex
information in our design, resulting in the following DESeq2 formula: design = ~sex + cell_types +
breed + condition, with the condition here being the status of the sample (with normal tissue being a
control for cell type heterogeneity versus tumoral tissue). To take into account low gene counts (which
are especially the case for lncRNAs), we used the recently developed lfcShrink method with the type =
apeglm option [22] to better estimate log-fold changes for poorly expressed genes. To test whether the
log-fold change linked to oral melanoma was different between breeds, we added an interaction to the
design, such as breed:condition.
2.3. Identification of Human Orthologous lncRNAs
For each canine lncRNA gene belonging to the “canFam3.1-plus” annotation, we projected all
of its exons onto the canine genome, resulting in one representative “meta-transcript” sequence per
gene. These sequences were then mapped onto the human genome assembly version GRCh38, using
minimap2 [23] with the following parameters -ax splice -t16, and only primary alignments being
retained in the case of multiple mappings. Based on the CIGAR field, sequence identity was defined as
the number of matching bases over the number of alignment columns. Finally, human orthologous
coordinates were compared with the GENCODE (v29) annotation of the lncRNA exons [8,24] using
the bedtools [25] intersect program (after BAM to BED12 file format conversion) with the following
parameters: -s -split, in order to assign orthologous relationships.
2.4. Weighted Gene Coexpression Network Analysis
A weighted gene coexpression network analysis (WGCNA) was carried out on the 52 RNA-Seq
reads, using the R package WGCNA 1.66 [26]. The program utilizes a similarity measure to summarize
the relationship between all pairs of genes, using expression data normalized as TPM to create a
correlation matrix. We used the signed WGCNA coexpression measure. To identify coexpression
modules, we used the ‘soft-thresholding procedure’. WGCNA utilizes a similarity measure to
summarize the relationship between all pairs of gene expression data across the data set, to create
a correlation matrix. Co-expression modules are defined as branches of a cluster tree, using a
dynamic branch-cutting approach. Therefore, co-expression modules are clusters of co-expressed
genes identified by hierarchical cluster analysis.
Constructing a weighted gene network entails the use of a soft-threshold score that assigns a
connection weight to each gene pair. The co-expression similarity is raised against the soft thresholding
power, in order to calculate adjacency. For soft thresholding, we used the two adjacency functions that
convert the co-expression measure to a connection weight. First, the scale-free fit index is a function of
the soft-thresholding power. Second, the mean connectivity is a function of the soft-thresholding power.
We set the soft-threshold to 7, to avoid the selection of an arbitrary cut-off. The weighted separation of
co-expression was achieved by the transformation of the correlation matrix in an adjacency matrix,
using default values. Gene profiles that had a low expression and/or did not vary sufficiently across
each of the data sets were eliminated. A total of 3,830 genes met these criteria. We performed principal
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component analysis, and used the first principal component (module eigengene; ME) to summarize
the standardized module expression data.
To assess the potential associations between coexpressed gene modules and the melanoma
condition, a single-column vector of clinical data for each breed and for all breeds considered together
was defined and utilized. An association analysis was performed by using the module-trait WGCNA
method to perform correlation analysis of the ME with clinical traits. Correlations and the corresponding
p-values allowed for an inspection of the most significant associations.
Intramodular analysis was performed to identify genes with high gene significance and module
membership measures, as recommended by WCGNA procedures. Genes with high significance (>0.5)
for each variable, as well as high module membership (>0.5) in interesting modules were extracted.
2.5. Gene Set Enrichment Analysis
We conducted Gene Set Enrichment Analysis using the GSEA webserver [27], to construct
meaningful annotation from the GO of genes (mRNAs), defined a priori by the WGCNA modules. The
ontology that was used covered the domain of biological processes (BP).
3. Results
3.1. Whole-Transcriptome Sequencing of Oral Melanomas
We sampled 39 oral melanomas from three breeds (16 golden retrievers, 13 Labrador retrievers
and 10 poodles) that were classified with respect to their oral melanoma locations, which included the
tongue for 26% of the annotated cases, followed by the maxilla (18%) (Supplementary Materials Table
S1).
Combining healthy and tumor samples, 5.7 billion sequencing reads were generated, with an
average of 107 million reads per sample (Supplementary Materials Table S2). After quality control and
trimming of the adapters, between 89% and 96% of the reads could be mapped onto both the canine
genome assembly (canFam3.1) and the “canFam3.1-plus” annotation [5,6], using the state-of-the-art
bioinformatic protocol described in Djebali et al. [17]. Amongst the lncRNA genes, we focused on long
intergenic ncRNAs (lincRNA; n = 5651) and antisense lncRNAs (antisense; n = 4793), thus removing
sense intronic lncRNAs which may correspond to the misannotation of coding alternative isoforms,
and observed that 59.0% and 58.5% respectively could be considered as being expressed, using a soft
filter of 10 reads in total per gene. In comparison, 87.6% of the total number of protein coding genes
(n = 21,810) were retained, using the same threshold.
3.2. Analysis of Differentially Expressed Genes (DEG) in Mucosal Melanomas
We first performed quality control of the samples by using a PCA with all gene counts, as
normalized by the DESeq2 program (size factors normalization) (Figure 1a). This revealed a clear
distinction of the samples, with the first principal component distinguishing the control from the
tumor samples in the three breeds. A similar distribution was observed when taking into account
only the lncRNA-normalized counts, although the percentage of the explained variance was slightly
lower (Supplementary Materials Figure S2). We next used DESeq2 to identify differentially expressed
genes (both lncRNAs and mRNAs) by controlling for specific covariates: breed, sex, and cell-type
heterogeneity between the samples (see Methods). For the latter, expression data was incorporated
into the xCell program [21], and samples were then clustered according to their enrichment within
the 64 cell-type signatures used by the program (Supplementary Materials Figure S1). Control
samples were found to be enriched in keratinocyte-like and skeletal muscle cells, while tumor samples
tended to be enriched in melanocyte cells. Using this multi-factor experimental design, we identified
417 differentially expressed lncRNAs between tumor and control samples, using an absolute log2
fold-change (|lFC|) > 1.5, and an adjusted p-values (padj) < 0.05 (see methods) (Figure 1b). From a
cross-check of the DE analysis, we found that the MDM2 proto-oncogene, shown to be recurrently
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gained in human non-cutaneous melanomas [28], was almost four times more highly expressed in
canine oral melanoma tumors than in controls (lFC = 1.96; padj = 0.02). Similarly, we observed a
significantly lower expression of the BUB1 gene in our cohort of canine melanomas (lFC = −1.06; padj =
0.02), in accordance with recent findings showing recurrent deletions of BUB1 in mucosal melanomas
using a cross-species strategy, including human, horse, and dog samples [3]. Among the 417 DE
lncRNAs, 272 lncRNAs were down-regulated and 145 were up-regulated.
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Figure 1. Expression analysis of the 52 oral melanoma samples. (a) Principal component analysis 
(PCA) of the 52 samples, based on gene-normalized counts, with control and tumor samples in blue 
and orange, respectively; (b) M-A plot representing log2-fold gene changes between tumors and 
controls over the mean of the normalized counts, with red points corresponding to significantly DE 
genes, with an adjusted p-value < 0.05, and without a log-fold change threshold; genes falling outside 
of the window are plotted as open triangles. 
3.3. Comparative Genomics of Canine Differentially Expressed lncRNAs 
Previous comparative genomic analysis [6] allowed us to identify a set of orthologous lncRNAs 
between human and dog, using a synteny-based approach. Here, we sought to annotate novel 
orthologous lncRNAs between dog and human by directly mapping DE lncRNAs sequences onto 
the human genome, using the minimap2 program [23] (see Methods). With the human genome 
assembly version GRCh38 defined as the target sequence, we aligned 33% of canine DE lncRNAs (n 
= 140) with a minimum identity of 70%. Amongst those, 26 matched to an already 
GENCODE-annotated [24] non-coding gene (Table 1). Most notably, we showed that several 
cancer-associated annotated lncRNAs in human are differentially expressed in canine mucosal 
melanomas. This included the down-regulation of SOX21-AS1 (lFC = −2.97, padj = 0.003) (Figure 2a), 
already shown to be silenced in oral cancers [30], and the overexpression of the CASC15 gene 
(Cancer Susceptibility Candidate 15) (lFC = 3.3, padj = 2.8 × 10−5) (Figure 2b), whose RNA level has also 
been linked to cutaneous melanoma and phenotype switching in humans [31]. This analysis also 
shed light on 114 canine DE lncRNAs, which aligned to the human genome (identity > 70%) but 
without any known annotated transcripts by GENCODE, potentially highlighting novel human 
lncRNAs (Supplementary Materials Table S3). 
Figure 1. Expression analysis of the 52 oral melanoma samples. (a) Principal component analysis (PCA)
of the 52 samples, based on gene-normalized counts, with control and tumor samples in blue and
orange, respectively; (b) M-A plot re resenting log2-fold gene changes between tumors and controls
over the mean of the ormalized counts, with red points corresponding to significantly DE genes,
with an adjusted p-value < 0.05, and without a l g-fold change threshold; genes falling outside of th
windo are plott d as open triangles.
Although most canine lncRNAs have not yet been functionally characterized, one notable exception
was given by the lncRNA ZEB2-AS, transcribed in an antisense orientation to the ZEB2 mRNA, which
was almost 14 times more highly expressed in tumors compared to normal tissues (lFC = 3.79, padj =
2.7 × 10−8). Interestingly, this lncRNA has been shown to be involved in the regulation of ZEB2 mRNA
during the epithelial–mesenchymal transition (EMT) in human cell lines [29].
3.3. Comparative Genomics of Canine Differentially Expressed lncRNAs
Previous comparative genomic analysis [6] allowed us to identify a set of orthologous lncRNAs
between human and dog, using a synteny-based approach. Here, we sought to annotate novel
orthologous lncRNAs between dog and human by directly mapping DE lncRNAs sequences onto the
human genome, using the minimap2 program [23] (see Methods). With the human genome assembly
version GRCh38 defined as the target sequence, we aligned 33% of canine DE lncRNAs (n = 140) with
a minimum identity of 70%. Amongst those, 26 matched to an already GENCODE-annotated [24]
non-coding gene (Table 1). Most notably, we showed that several cancer-associated annotated
lncRNAs in human are differentially expressed in canine mucosal melanomas. This included the
down-regulation of SOX21-AS1 (lFC = −2.97, padj = 0.003) (Figure 2a), already shown to be silenced in
oral cancers [30], and the overexpression of the CASC15 gene (Cancer Susceptibility Candidate 15)
(lFC = 3.3, padj = 2.8 × 10−5) (Figure 2b), whose RNA level has also been linked to cutaneous melanoma
and phenotype switching in humans [31]. This analysis also shed light on 114 canine DE lncRNAs,
which aligned to the human genome (identity > 70%) but without any known annotated transcripts by
GENCODE, potentially highlighting novel human lncRNAs (Supplementary Materials Table S3).
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Table 1. List of DE lncRNAs conserved with human GENCODE non-coding genes. Genes are ordered
by ascending log2-fold change (lFC).
canfam3.1+_id Dog EnsEMBL ID Dog Gene Biotype lFC Human Gene Name Dog/Human Identity
RLOC_00034858 NA lincRNA −3.693 AC016903.1 0.770
RLOC_00028807 NA antisense −3.409 AC010503.4 0.740
RLOC_00001518 NA lincRNA −3.055 EPHA1-AS1 0.717
RLOC_00010776 NA lincRNA −2.974 SOX21-AS1 0.732
RLOC_00026330 NA lincRNA −2.669 MIR29B2CHG 0.804
RLOC_00030709 NA antisense −2.659 LINC02586 0.709
RLOC_00012258 NA lincRNA −2.258 TOB1-AS1 0.717
RLOC_00019548 NA lincRNA −2.214 AL049536.1 0.768
RLOC_00015465 NA lincRNA −2.201 LINC01588 0.794
RLOC_00011768 NA antisense −2.050 AC005821.1 0.714
RLOC_00011720 NA antisense −1.597 LINC02079 0.969
RLOC_00014809 NA lincRNA 1.698 AC062015.1 0.923
RLOC_00002398 NA antisense 1.782 NR2F1-AS1 0.820
RLOC_00032616 NA lincRNA 1.868 HOXD-AS2 0.754
RLOC_00023326 NA antisense 1.989 RASSF8-AS1 0.713
RLOC_00032620 NA antisense 2.030 HAGLR 0.786
RLOC_00020381 NA lincRNA 2.188 TRAM2-AS1 0.745
RLOC_00024264 NA lincRNA 2.634 AC133644.3 0.979
RLOC_00021953 NA lincRNA 3.359 CASC15 0.942
RLOC_00011077 NA lincRNA 3.673 LINC01301 0.780
RLOC_00008433 ENSCAFG00000028700(ZEB2-AS1) lincRNA 3.796 ZEB2-AS1 0.839
RLOC_00013073 NA lincRNA 3.797 AC006450.3 0.746
RLOC_00018365 NA lincRNA 4.403 AC090692.1 0.755
RLOC_00022953 NA antisense 4.910 HOXC-AS3 0.757
RLOC_00002254 NA antisense 4.958 STARD4-AS1 0.903
RLOC_00025419 NA lincRNA 5.758 SNAP25-AS1 0.987
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Figure 2. Differential expression of dog–human-conserved lncRNAs. (a) Down-regulation of the 
SOX21-AS1 lncRNA between control samples (blue) versus tumor samples (orange), with the log2 of 
normalized counts on the y-axis; lines connect matched samples from the same individuals. (b) Same 
representation for the up-regulation of the lncRNA CASC15. 
Table 1. List of DE lncRNAs conserved with human GENCODE non-coding genes. Genes are 
ordered by ascending log2-fold change (lFC). 
canfam3.1+_id Dog EnsEMBL ID Dog Gene Biotype lFC Human Gene Name Dog/Human Identity 
RLOC_00034858 NA lincRNA −3.693 AC016903.1 0.770 
RLOC_00028807 NA antisense −3.409 AC010503.4 0.740 
RLOC_00001518 NA lincRNA −3.055 EPHA1-AS1 0.717 
RLOC_00010776 NA lincRNA −2.974 SOX21-AS1 0.732 
RLOC_00026330 NA lincRNA −2.669 MIR29B2CHG 0.804 
RLOC_00030709 NA antisense −2.659 LINC02586 0.709 
RLOC_00012258 NA lincRNA −2.258 TOB1-AS1 0.717 
RLOC_00019548 NA lincRNA −2.214 AL049536.1 0.768 
RLOC_00015465 NA lincRNA −2.201 LINC01588 0.794 
RLOC_00011768 NA antisense −2.050 AC005821.1 0.714 
RLOC_00011720 NA antisense −1.597 LINC02079 0.969 
RLOC_00014809 NA lincRNA 1.698 AC062015.1 0.923 
RLOC_00002398 NA antisense 1.782 NR2F1-AS1 0.820 
RLOC_00032616 NA lincRNA 1.868 HOXD-AS2 0.754 
RLOC_00023326 NA antisense 1.989 RASSF8-AS1 0.713 
RLOC_00032620 NA antisense 2.030 HAGLR 0.786 
RLOC_00020381 NA lincRNA 2.188 TRAM2-AS1 0.745 
RLOC_00024264 NA lincRNA 2.634 AC133644.3 0.979 
RLOC_00021953 NA lincRNA 3.359 CASC15 0.942 
RLOC_00011077 NA lincRNA 3.673 LINC01301 0.780 
RLOC_00008433 ENSCAFG00000028700 (ZEB2-AS1) lincRNA 3.796 ZEB2-AS1 0.839 
RLOC_00013073 NA lincRNA 3.797 AC006450.3 0.746 
RLOC_00018365 NA lincRNA 4.403 AC090692.1 0.755 
RLOC_00022953 NA antisense 4.910 HOXC-AS3 0.757 
RLOC_00002254 NA antisense 4.958 STARD4-AS1 0.903 
RLOC_00025419 NA lincRNA 5.758 SNAP25-AS1 0.987 
3.4. Inferring Functions of Differentially Expressed lncRNAs 
We conducted an unsupervised expression analysis of lncRNAs, utilizing a WGCNA [26] 
based on the 52 RNA-Seq samples. The advantage of WGCNA is that it transforms gene expression 
data into co-expression modules, providing insights into signaling networks that may be 
responsible for the development and progression of oral melanomas. We included protein-coding 
genes (n = 21,810) to identify coexpressed modules that reveal relationships between lncRNAs and 
mRNAs, suggest common biological roles, and inform potential roles for lncRNAs. 
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3.4. Inferring Functions of Differentially Expressed lncRNAs
We conducted an unsupervised expression analysis of lncRNAs, utilizing a WGCNA [26] based
on the 52 RNA-Seq samples. The advantage of WGCNA is that it transforms gene expression data
into co-expression modules, providing insights into signaling networks that may be responsible for
the development and progression of oral melanomas. We included protein-coding genes (n = 21,810)
to identify coexpressed modules that reveal relationships between lncRNAs and mRNAs, suggest
common biological roles, and inform potential roles for lncRNAs.
3.4.1. Correlating Transcriptional Networks and Traits using Co-Expression Analysis
In the initial phase of the WGCNA, we identified 59 coexpression modules in an unsupervised
manner. Hierarchical clustering analysis was performed, and a dendrogram was used to represent
coexpression modules, as shown by color assignments (Figure 3). The coexpression modules included
121 lncRNAs on average (a range of 10 to 627).
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of the eigengene module with the gene expression profile. We identified four modules (hereafter
termed brown, medium-orchid, yellow, and tan) that were significantly associated with the melanoma
status, with two modules being positively associated (PCC = +0.64, p = 6 × 10−7 ME yellow; PCC=
+0.54, p = 5 × 10−5 for ME Tan), while the two other modules showed significant but opposite PCC
associations with melanoma (ME brown, PCC = −0.90, p = 8 × 10−20; ME medium-orchid, PCC = −0.87,
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We considered only lncRNAs identified by the DE analysis in the coexpression analysis (n = 417)
to overcome the heterogeneity bias between tumor and control cell types. A total of 215 DE lncRNAs
(51.5%) also belonged to coexpressed modules with significant PCCs with melanoma status, such as
the dog–human-conserved lncRNA SOX21-AS1 which was found to be down-regulated in dog MM.
In light of their correlations with cancer, dysregulated lncRNAs were classified into two categories;
30 belonged to modules with significant positive correlations, and 185 were in modules that yielded
significant although opposite PCC.
3.4.2. Using Transcriptional Networks for Inferring lncRNA Functions
We used the lncRNA:mRNA correlated transcriptional networks constructed by WGCNA to infer
the main functions of the lncRNAs, using the ‘guilt-by-association’ principle [32]. The functional
implication of coexpressed mRNAs within the four modules (brown, medium-orchid, yellow, and tan)
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that were significantly associated with MM was evaluated via gene set enrichment analysis, using the
GSEA tool [27]. Our data showed that both positive and negative modules were significantly associated
with specific but distinct GO biology process terms. As shown in Figure 5, genes involved in the
positively associated module were enriched for GO terms involved in “cell cycle”, “cell cycle process”
or “mitotic cell cycle” for the yellow module, and “chromosome organization”, “cellular response to
stress”, and “DNA metabolic process” for the tan module. These GO terms are connected with cancer,
and implicated the replication and segregation of genetic material, and progression through the phases
of the mitotic cell cycle.
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3.4.3. Breed-Specific lncRNAs Associated with Oral Melanoma
The design of our study, which included three distinct breeds predisposed to MM, made it possible
to integrate both the coexpression module analysis and the differentially expressed lncRNAs, for each
separate breed. Given the low number of control samples for Labrador retrievers, we focused our
analysis on the pairwise comparisons between golden retrievers and poodles. Using WGCNA, the
analysis of the poodle breed produced a significant correlation for eight modules (six with PCC > 0.8,
p < 2 × 10−12 and two PCC < −0.8, p < 2 × 10−15) (Supplementary Materials Figure S3). From these
modules, the gene set enrichment analysis showed that the GO terms (biological process) that were most
significantly enriched were “regulation of gene expression”, “chromatin organization”, and “chromatin
modification” (orange module, Supplementary Materials Figure S4). Complementary to this analysis,
we refined the DESeq2 experimental design, which previously computed the global melanoma effect
while controlling for differences due to the breeds, to search for DE lncRNAs only in poodles, and not in
golden retrievers (see Methods). Our analysis identified a panel of 11 lncRNAs that were significantly
DE only in poodles (|lFC| > 1.5 and padj < 0.05), and which belong to WGCNA modules associated
to poodles (Supplementary Materials Table S5). For instance, we observed that the most significant
DE lncRNA (RLOC_00005829) is down-regulated in poodles (lFC = −5.99, padj = 8.1 × 10−7), while
its expression is not significantly altered in golden retrievers (padj = 0.61) (Supplementary Materials
Figure S5). Concordantly, this lncRNA was not considered as being DE (padj = 0.54) in the first
design when the tumor effect was controlled for differences due to breeds. Finally, we mapped the
RLOC_00005829 sequence on the human genome, and showed that it clearly aligned to the COLCA1
gene (identity = 61.1%), a GENCODE-annotated antisense lncRNA [24] that was already associated
with human colorectal cancer by GWAS [33].
For golden retrievers, the coexpression analysis produced significant correlations for four modules
(PCC < −0.8, p < 3 × 10−20). Similarly, the DE analysis identified a panel of seven lncRNAs only
found to be differentially expressed in golden retriever samples and not in poodles, but these were not
identified with WGCNA (Supplementary Materials Table S5).
4. Discussion and Conclusions
Long non-coding RNAs (lncRNAs) are key regulators in many biological processes and they are
often dysregulated in cancers [34], including cutaneous melanoma [13]. We investigated lncRNAs of
the canine model as being potential cancer markers for mucosal melanomas in humans. Our findings
show the existence of a genetic basis and expression variation involving long non-coding RNAs in oral
mucosal melanomas in dogs from three breeds (golden retrievers, Labrador retrievers, and poodles),
with an increased risk of developing oral mucosal melanomas.
In this study, bioinformatic analyses identified more than 400 dysregulated lncRNAs that
discriminated canine oral melanoma tumors from control samples. We further pinpointed one
down-regulated (SOX21-AS) and two up-regulated (CASC15 and ZEB2-AS) DE lncRNAs (inferred as
“onco-lncRNAs”) [35,36] in canine oral melanoma, that were significantly conserved with humans,
and already associated with human cancers. These results provide a novel resource for candidate
biomarkers, for which further in vitro and in vivo experimental validations will be required.
Although we used bulk RNA-Seq to analyze dysregulated lncRNAs in canine oral melanomas,
we adopted an enrichment-based computational analysis to control for covariates such as cell-type
heterogeneity between samples. Importantly, the xCell program, which was used to compute these
enrichments, includes melanoma-related cell-types from the Tirosh et al. single-cell RNA-Seq study [37],
such as malignant, immune, and endothelial cells. In melanomas, the distinct subtypes that most likely
harbor multiple cell types and high genetic heterogeneity are thought to play a role in the development
and progression of tumors. Future directions to explore the distinct genotypic and phenotypic
states of the tumors will involve directly performing single-cell RNA sequencing on oral mucosal
melanomas. Furthermore, the expression of lncRNAs is highly tissue- and cancer-specific [8,34] and
this is particularly relevant for studying cells of the same tumor and/or tissue that exhibit transcriptional
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heterogeneity [38]. In our study, we also observed that the tissue specificity, measured from canine
normal tissues [6], was significantly higher for DE lncRNAs than for DE mRNAs (p-value= 2.8 × 10−9,
Wilcoxon’s rank-sum test), reinforcing the attractiveness of lncRNAs as potential biomarkers of
oral melanomas.
We also report a weighted gene coexpression network analysis (WGCNA) that constructed
59 modules by an unsupervised analysis of gene expression profiles. The WGCNA method was
further used to detect the relationship between the lncRNA expression profiles and the melanoma
status. WGCNA has many advantages over other clustering methods, since the analysis uses a
‘soft-thresholding procedure’ to avoid the selection of an arbitrary cut-off. It also focuses on the
association between coexpression modules and clinical features, and the results have robust reliability
and biological significance. Genes in the same module are considered to be related with each other
by their functions. We identified four coexpression modules that are related to oral melanoma for
all breeds studied, and specific DE lncRNAs for the poodle and golden retrievers breeds. Thus, this
study led to the identification of biologically relevant modules and hub lncRNAs that could serve as
biomarkers for the detection of mucosal melanomas [39].
To give biological meaning to identify lncRNAs, we conducted a gene set enrichment analysis.
These analyses showed clear differences in enriched GO (BP) terms between the different modules,
which were largely associated with different functions. As a result, modules containing up-regulated
genes were found to be mainly enriched in cancer-associated pathways, implicating the replication
and segregation of genetic material, and its progression through the mitotic cell cycle phases. The
dysregulated lncRNAs of these modules could possibly have a role in cell cycle or cell proliferation.
Modules with down-regulated genes were largely involved in carbohydrate metabolic processes.
Carbohydrates and glucose can have important effects on the proliferation of tumor cells. It has been
reported that most malignant cells are dependent on the availability of glucose in the blood for their
energy, and that they are not able to metabolize it, especially in case of mitochondrial dysfunction [40].
Gene expression profiling is actively investigated as a clinical biomarker and diagnostic tools
to detect multiple cancer types and distinct stages. However it is challenging to take into account
the variability of gene expression, and thus the underlying functions of genes in populations of
different ethnic origins [41]. Here, we used the unique features of the dog model, and its diversity
and breed structure, to study the expression variations of lncRNAs that are associated with mucosal
melanomas between breeds. We have identified lncRNAs that are differentially expressed only in
melanomas sampled in poodles, such as the antisense lncRNA COLCA1. Therefore, the variation in
lncRNA expression identified in dog breeds may help to better characterize the observed disparities
and heterogeneity of mucosal melanomas in humans.
Identifying the dysregulation of lncRNA expression in mucosal melanomas provides novel tools
and resource that can serve as diagnostic and therapeutic targets. Here, we show by the identification of
conserved dog–human lncRNAs, that they can also provide key markers in human mucosal melanomas.
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